This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
On 26 January 2024, the European Commission published a report on competition enforcement in the pharmaceutical sector, highlighting the role of EU competition law in safeguarding market participants and consumers, particularly amid the challenges posed by the Covid-19 crisis.
Hamilton Lane has acquired a significant equity interest in Cosette Pharmaceuticals from Avista Capital Partners and its co-investors, according to a news release. By: McGuireWoods LLP
On June 1, 2023, the Federal Trade Commission (FTC) and the Antitrust Division of the US Department of Justice (DOJ) released a summary of a workshop jointly held by the agencies in June 2022 titled “Future of Pharmaceuticals: Examining the Analysis of Pharmaceutical Mergers.”
Department of Justice Antitrust Division, recently released a summary of the Agencies’ June 2022 joint workshop titled “The Future of Pharmaceuticals: Examining the Analysis of Pharmaceutical Mergers.” By: Mintz
Integrating AI tools into drug discovery introduces a mix of opportunities and challenges for startups and large pharmaceutical companies. These challenges often center on intellectual property (IP) risks, licensing considerations, M&A due diligence, and documentation practices. By: Fenwick & West LLP
While the two companies evidently have some history together, this new deal is reportedly tied to Phillip Morris’ interest in acquiring Syqe’s metered-dose, pharmaceutical-grade inhaler that dispenses precise doses of medical cannabis to patients. By: Bradley Arant Boult Cummings LLP
On March 26, 2024, Skadden hosted a discussion on key developments in antitrust enforcement in the pharmaceuticals and life sciences sectors. By: Skadden, Arps, Slate, Meagher & Flom LLP
The post Avista-backed Cosette Pharmaceuticals acquires women’s sexual health brand Vyleesi appeared first on PE Hub. The seller was Palatin Technologies Inc.
Cephalon, Inc., 2018-0075-SG (Del. 30, 2024) - Stockholder representatives of an acquired corporation brought claims alleging that defendants had failed to use contractually-required commercially reasonable efforts to commercialize an acquired drug asset for a particular use. By: Morris James LLP
The post PE-backed Alcami acquires Pacific Pharmaceutical Services appeared first on PE Hub. Alcami is a contract development and manufacturing organization.
Nasdaq: BIIB) and Reata Pharmaceuticals, Inc. CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. Nasdaq: RETA) today announced the companies have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3
On September 11-12, we had the pleasure of attending the LSX World Congress USA in Boston, where leaders discussed the challenges and opportunities of M&A and partnerships in the pharmaceutical sector. By: A&O Shearman
Bass, Berry & Sims brought a team of four attorneys from our Specialty Pharmacy & Pharmaceuticals and 340B Program Services practice groups to join the fun. Asembia’s 20th Annual Specialty Pharmacy Summit once again brought investors and operators in the specialty pharmacy ecosystem to Las Vegas for learning sessions and networking.
Morgan Healthcare Conference in San Francisco, which also saw the announcement of major acquisitions by large players in the pharmaceutical space. The timing of the announcement coincided with the start of the 42nd Annual J.P. By: Knobbe Martens
Pharmaceutical contract development and manufacturing firms provide a range of services to small and large pharmaceutical enterprises under a contract. Pharmaceutical contract development and manufacturing firms provide a range of services to small and large pharmaceutical enterprises under a contract.
The post Gurnet Point and Novo Holdings complete take-private buyout of Paratek Pharmaceuticals appeared first on PE Hub. The purchase price is about $462 million.
designs and produces solutions for the biopharmaceutical, pharmaceutical and medical device markets and aerospace industries. New Mountain Capital will sell ILC Dover to Ingersoll Rand for about $2.3 billion, according to industry reports. ILC, founded in 1947 and based in Frederica, Del., By: McGuireWoods LLP
While the year saw an overall decline in M&A activity (down 17% from 2022), total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. By: Cooley LLP
The European Commission (EC) has published its latest report on competition enforcement in medicines and medical products. Key takeaways are that: EU and Member State authorities imposed multiple material antitrust fines from 2018-2022, totalling approx. EUR780 million. By: Allen & Overy LLP
But one portion of the pharmaceutical industry is bucking this trend in a major way. Over the past few years economic headwinds have resulted in fewer deals, with companies and private equity firms alike reassessing where to spend money.
August 01, 2024: SEAM Group, a B2B business products and services company that provides safety, reliability, maintenance, and enterprise asset management services in the hospitality, food processing, and pharmaceutical industries, was acquired by ABB for an undisclosed amount.
The post Gurnet Point and Novo Holdings to acquire Paratek Pharmaceuticals for $462m appeared first on PE Hub. Oaktree Capital Management will provide $175 million in debt financing for this deal.
Among these are two cross-agency Requests for Information (RFIs) about anticompetitive transactions, an online portal to enable anyone to report anticompetitive business practices, a new Department of Justice (DOJ) task force and a new Federal Trade Commission (FTC) investigation into certain Teva Pharmaceuticals’ patent.
We were fortunate to have a mix of expert perspectives at the table, representing large pharmaceutical companies, investors, By: Mintz Asset Sale,” with business development leaders from GSK, Johnson & Johnson, Locust Walk, and Astria Therapeutics.
Nonetheless, on September 1, 2023, (the Friday before Labor Day), the FTC announced a conduct consent decree to end its challenge to the Amgen-Horizon pharmaceutical merger. By: Mintz - Antitrust Viewpoints
The reforms are particularly relevant to the technology and pharmaceutical. The UK DMCC forms part of a global trend to focus merger review increasingly on vertical concerns and concerns about eliminating nascent competition, including by so-called “killer acquisitions” of firms perceived as future competitive threats. By: Morgan Lewis
To that end, the DOJ recently announced its decision to decline to prosecute Lifecore Biomedical, a pharmaceutical and medical device manufacturer, despite evidence that employees of Lifecore’s former US subsidiary bribed Mexican government officials in violation of the Foreign Corrupt Practices Act.
The post Nordic Capital bets it can help the pharmaceutical industry speed up technology adoption appeared first on PE Hub. Nordic is acquiring the majority stake in IntegriChain, a Philadelphia-based provider of technology for the life sciences industry, from Accel-KKR.
ACN, based in Dallas, is a clinical site platform serving patients, pharmaceutical sponsors and contract research organizations. Amulet Capital Partners has announced it has acquired Alliance Clinical Network (ACN). By: McGuireWoods LLP
16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” PRINCETON, N.J., ANI” or “the Company”) (Nasdaq: ANIP) today announced the completion of its previously announced acquisition of Alimera Sciences, Inc. Nasdaq: ALIM) (“Alimera”).
We organize all of the trending information in your field so you don't have to. Join 38,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content